辛伐他汀对冠心病合并高血压患者尿蛋白的影响

目的探讨辛伐他汀对冠心病合并高血压患者尿蛋白的影响。方法选取内蒙古自治区人民医院2008年4月至2011年1月收治冠心病合并高血压患者110例，采用随机数字表法分为对照组和辛伐他汀组，每组各55例；分别给予安慰剂和辛伐他汀40mg／d，疗程均为6个月；比较两组患者治疗前后TG（甘油三酯）、TC（总胆固醇）、HDL—C（高密度脂蛋白）、LDL—C（低密度脂蛋白）、血肌酐（Cr）、24h尿微量白蛋白（UMA）、血清超敏C反应蛋白（hsCRP）及血压水平等。结果两组患者治疗前TG、TC、HDL—C、LDL～C、Cr、UMA及hsCRP水平组间比较无显著差异（P〉0．05）；治疗后两组患者TG、TC、HDL—C、LDL—C、Cr、UMA及hsCRP水平较治疗前均明显改善，且辛伐他汀组患者治疗后TG、TC、HDL—C、LDL—C、Cr、UMA及hsCRP水平明显优于对照组（P〈0．05）；同时两组患者治疗前后收缩压、舒张压水平比较差异无统计学意义（P〉0．05）。结论辛伐他汀能够有效改善冠心病合并高血压患者尿蛋白水平，可用于早期肾病临床治疗。

Effect of simvastatin on urinary protein of patients with coronary heart disease complicated with hypertension

Objective To investigate the effects of simvastatin in urinary protein on patients with coronary heart disease complicated with hypertension. Methods Totally 110 cases of coronary heart disease patients complicated with hyper- tension were selected in our hospital from 2008 April -2011 year January , were randomly divided into control group and simvastatin group, 55 cases in each group; given either placebo or simvastatin 40mg/d, course of treatment was 6 months ; The TG （ triglyceride）, TC （ total cholesterol）, HDL - C （ high density lipoprotein）, LDL - C （ low density lipoprotein）, serum creatinine （Cr）, 24h urinary albumin （UMA）, serum high sensitive C reactive protein （hsCRP） and blood pressure level of two groups of patients before and after treatment were compared. Results Patients＇ TG, TC, HDL - C, LDL - C, Cr, UMA and hsCRP levels between control ~oup and simvastatin group before treatment showed no significant difference （P 〉 0. 05 ） ; The TG, TC, HDL - C, LDL - C, Cr, UMA and hsCRP levels after treatment in two groups of patients were significantly improved than before treatment, and the effect of simvastatin in pa- tients after treatment, TG, TC, HDL -C, LDL -C, Cr, UMA and hsCRP levels were significantly better than those the control group （ P 〈 0. 05 ） ; while stheystolic pressure, diastolic pressure level of control group and simvastatin group be- fore and after treatment in patients were compared, difference not had statistical significance （ P 〉 0. 05）. Conclusions The simvastatin can effectively improve the coronary heart disease patients with hypertension and urinary protein lev- els, can be used for the clinical treatment of early nephropathy.